An antibody–drug conjugate for small-cell lung cancer

The article discusses a new treatment approach for small-cell lung cancer (SCLC), which remains a disease with poor prognosis despite improvements in therapy. The standard second-line treatment uses topotecan, a topoisomerase I inhibitor, which provides only modest benefit and causes significant toxicity. A new approach utilizes an antibody-drug conjugate, representing an advance in treating this aggressive form of cancer. Treatment has improved with the introduction of checkpoint inhibitors into first-line therapy. The article highlights the need for new therapeutic options for SCLC patients. This new antibody-drug conjugate technology represents a promising direction in oncology.